Developer docs
API playgroundTry for free, no card

Search company profiles

Vicora

Full company profile

uuid00032b1

Namestring
Vicora
Legal namestring
Vicora, Inc.
Websiteurl
vicora.net
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Vicora is a privately held, pre-commercialization medical device company headquartered in Buffalo, New York, developing the Vibrato thrombectomy system, described as the world's first catheter with integrated distal tip vibration. The system targets mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures, addressing a US market of approximately 900,000 annual DVT cases, a 15% mortality rate in hospitalized PE patients, and a documented 5% incidence of clot fragment migration ("lollipopping" or "corking") during treatment. The device is designed to require no additional capital equipment, with optimized trackability intended to ease navigation through vascular anatomy.

Vicora completed its GLP pre-clinical study in January 2026 but has not yet received FDA clearance and is not approved for sale in any country. The intended go-to-market is direct enterprise sales to hospital interventional radiology and interventional cardiology departments performing thrombectomy procedures. The company is structured as the first portfolio company of Egret Healthcare Ventures, with a team of approximately 10 members covering CEO (Shawn Patterson), Executive Chairman (Bill Maggio), CFO, Chief Scientific Officer, Corporate Counsel, Quality & Regulatory Officer, Director of Engineering, Director of Administration, Director of Commercialization, and Corporate Relations.

The business model is currently one of capital-funded R&D rather than product revenue. Vicora has raised approximately $3.6M in a May 2025 round and filed a $6M SEC Form D offering (with $3.4M sold as of the filing), supplemented by non-dilutive funding from the University at Buffalo Center for Advanced Technology (UB CAT). Strategic partners include the Jacobs Institute, Yageo Group KEMET, Resolution Medical, Hemologyx, KCRI, and Rookery Labs, and the company has assembled a clinical advisory board drawn from Mayo Clinic, Karolinska University Hospital, UCLA, Montefiore Medical Center, and the Gates Vascular Institute.

Short descriptiontext

Vicora is a pre-commercialization medical device company developing the Vibrato thrombectomy catheter, the first catheter with integrated distal tip vibration, for clot removal in Deep Vein Thrombosis and Pulmonary Embolism procedures targeting hospital interventional radiology and cardiology departments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBuffalo, United States
HQ citystring
Buffalo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
thrombectomy catheter systems, vascular medical devices, deep vein thrombosis treatment, pulmonary embolism intervention, interventional radiology devices
Industry2 codes
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Vascular Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Pre-commercialization medical device company planning to sell thrombectomy catheters and associated products to hospitals and interventional radiology/cardiology departments upon FDA clearance.

vicora.net
2Securities Offering
TypeOne Time License
Description

SEC Form D filing for equity and pooled investment fund interests offering, with $6 million total offering amount and $3.4 million sold as of the filing date.

sec.gov
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vicora is developing the Vicora Vibrato Thrombectomy System, described as the world's first catheter with an integrated distal tip vibration mechanism designed for mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures. The device is intended for use by interventional radiologists and interventional cardiologists in hospital settings, and requires no additional capital equipment for operation. The product is currently in pre-clinical testing (GLP study completed January 2026) and is not yet FDA cleared or commercially available.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 900,000 DVT cases annually in the US creating substantial addressable market
+2 more records
Product overview1 text field

Vicora offers a single unified product: the Vicora Vibrato Thrombectomy System. This is the world's first catheter with an integrated distal tip vibration mechanism designed for clot removal procedures. The system targets Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) treatment. The device is currently in pre-clinical testing (GLP study completed January 2026) and has not received FDA clearance or approval. It is not available for commercial sale in any country.

Product and service1 record
1Vicora Vibrato Thrombectomy System
CategoryThrombectomy Medical Device
Description

The Vicora Vibrato is a thrombectomy catheter featuring an integrated vibrating distal tip mechanism intended for mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures. The device is designed for hospital interventional radiology and interventional cardiology departments, offers optimized trackability through vascular anatomy, and operates without requiring additional capital equipment. The product is currently in pre-clinical testing and has not received FDA clearance.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-25
Description

UB CAT (Center for Advanced Technology) awarded Vicora an R&D collaboration award in September 2024. The partnership provides funding and research support for life sciences development. Vicora also received UB CAT funding in December 2023.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partner listed on Vicora's website alongside other industry partners. The Jacobs Institute is focused on vascular innovation and medical device development, aligned with Vicora's thrombectomy technology focus.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partner providing electronic components expertise. KEMET is a leading global manufacturer of electronic components that may support Vicora's catheter technology development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partner listed on Vicora's website, specializing in medical device development with focus on interventional products.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a strategic partner on Vicora's website, providing potential commercialization or business development support.

6Hemologyx
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partner focused on hematology expertise relevant to Vicora's clot removal technology for DVT and PE treatment.

vicora.net
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a strategic partner on Vicora's website, providing research institute collaboration for medical device development.

8Eric Rudie
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a strategic partner on Vicora's website, providing industry expertise in medical device development.

vicora.net
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Penumbra's Indigo aspiration system is a leading mechanical thrombectomy platform for PE and DVT, directly competing with Vicora's Vibrato in the same hospital interventional radiology and cardiology call points.

TypeDirect peer
Description

Inari's FlowTriever (PE) and ClotTriever (DVT) are purpose-built mechanical thrombectomy devices and the closest direct competitors to Vicora Vibrato in the venous thromboembolism space.

TypeDirect peer
Description

AngioDynamics offers the AlphaVac and AngioVac mechanical thrombectomy systems, addressing PE and venous clot removal in the same hospital departments Vicora targets.

TypeDirect peer
Description

Argon manufactures the Option Elite and other venous intervention devices used for thrombectomy, positioning it as a competing supplier in DVT/PE clot-removal procedures.

TypeBroad incumbent
Description

Through its 2025 acquisition of Inari Medical, Stryker is now a major player in venous mechanical thrombectomy; it also operates broader neurovascular and vascular franchises that overlap with Vicora's procedural category.

TypeBroad incumbent
Description

Boston Scientific has peripheral vascular and interventional cardiology franchises that compete in hospital procedural suites where thrombectomy is performed, even though it does not lead in mechanical PE/DVT.

TypeBroad incumbent
Description

Teleflex markets Arrow vascular access and interventional catheters used in the same hospital IR/cardiology settings, representing an incumbent catheter vendor at accounts Vicora would target.

TypeBroad incumbent
Description

Medtronic has peripheral and coronary interventional portfolios that overlap with the procedural call points and purchasing relationships Vicora will rely on at hospital systems.

9Johnson & Johnson (Cerenovus)
TypeBroad incumbent
Description

Cerenovus, J&J's neurovascular business, is a leading player in catheter-based clot retrieval (notably for stroke), bringing catheter thrombectomy R&D and sales capability adjacent to Vicora's venous use cases.

TypeEmerging player
Description

Imperative Care is developing next-generation catheter-based vascular intervention technologies, with overlapping R&D culture and similar hospital call points in interventional radiology and cardiology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vicora

Vascular Medical Devicesvicora.net

Vicora is a pre-commercialization medical device company developing the Vibrato thrombectomy catheter, the first catheter with integrated distal tip vibration, for clot removal in Deep Vein Thrombosis and Pulmonary Embolism procedures targeting hospital interventional radiology and cardiology departments.

What Vicora does

Vicora is a privately held, pre-commercialization medical device company headquartered in Buffalo, New York, developing the Vibrato thrombectomy system, described as the world's first catheter with integrated distal tip vibration. The system targets mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures, addressing a US market of approximately 900,000 annual DVT cases, a 15% mortality rate in hospitalized PE patients, and a documented 5% incidence of clot fragment migration ("lollipopping" or "corking") during treatment. The device is designed to require no additional capital equipment, with optimized trackability intended to ease navigation through vascular anatomy.

Vicora completed its GLP pre-clinical study in January 2026 but has not yet received FDA clearance and is not approved for sale in any country. The intended go-to-market is direct enterprise sales to hospital interventional radiology and interventional cardiology departments performing thrombectomy procedures. The company is structured as the first portfolio company of Egret Healthcare Ventures, with a team of approximately 10 members covering CEO (Shawn Patterson), Executive Chairman (Bill Maggio), CFO, Chief Scientific Officer, Corporate Counsel, Quality & Regulatory Officer, Director of Engineering, Director of Administration, Director of Commercialization, and Corporate Relations.

The business model is currently one of capital-funded R&D rather than product revenue. Vicora has raised approximately $3.6M in a May 2025 round and filed a $6M SEC Form D offering (with $3.4M sold as of the filing), supplemented by non-dilutive funding from the University at Buffalo Center for Advanced Technology (UB CAT). Strategic partners include the Jacobs Institute, Yageo Group KEMET, Resolution Medical, Hemologyx, KCRI, and Rookery Labs, and the company has assembled a clinical advisory board drawn from Mayo Clinic, Karolinska University Hospital, UCLA, Montefiore Medical Center, and the Gates Vascular Institute.

Vicora firmographics

Firmographics
Name
Vicora
Legal name
Vicora, Inc.
Website
https://vicora.net
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Vicora is a pre-commercialization medical device company developing the Vibrato thrombectomy catheter, the first catheter with integrated distal tip vibration, for clot removal in Deep Vein Thrombosis and Pulmonary Embolism procedures targeting hospital interventional radiology and cardiology departments.
Ownership category
akta.pro rank

Vicora industry classification

Industry
Product category
Vascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Thrombectomy catheter systems
  • Vascular medical devices
  • Deep vein thrombosis treatment
  • Pulmonary embolism intervention
  • Interventional radiology devices

Where Vicora is headquartered

Location

Headquarters

HQ city
Buffalo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vicora business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Pre-commercialization medical device company planning to sell thrombectomy catheters and associated products to hospitals and interventional radiology/cardiology departments upon FDA clearance.
  2. Securities Offering: SEC Form D filing for equity and pooled investment fund interests offering, with $6 million total offering amount and $3.4 million sold as of the filing date.

Go-to-market motion1 record

Marketing channels3 records

Vicora product offering

Product offering

Core offering

Vicora is developing the Vicora Vibrato Thrombectomy System, described as the world's first catheter with an integrated distal tip vibration mechanism designed for mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures. The device is intended for use by interventional radiologists and interventional cardiologists in hospital settings, and requires no additional capital equipment for operation. The product is currently in pre-clinical testing (GLP study completed January 2026) and is not yet FDA cleared or commercially available.

Product overview

Vicora offers a single unified product: the Vicora Vibrato Thrombectomy System. This is the world's first catheter with an integrated distal tip vibration mechanism designed for clot removal procedures. The system targets Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) treatment. The device is currently in pre-clinical testing (GLP study completed January 2026) and has not received FDA clearance or approval. It is not available for commercial sale in any country.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vicora Vibrato Thrombectomy System The Vicora Vibrato is a thrombectomy catheter featuring an integrated vibrating distal tip mechanism intended for mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures. The device is designed for hospital interventional radiology and interventional cardiology departments, offers optimized trackability through vascular anatomy, and operates without requiring additional capital equipment. The product is currently in pre-clinical testing and has not received FDA clearance.

Quantifiable outcome

  • 900,000 DVT cases annually in the US creating substantial addressable market
  • +2 more outcomes

Companies that use Vicora

Customer profile

Segments2 records

Ideal customer profiles1 record

Vicora technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vicora partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • University at Buffalo (UB CAT)coreStrategic or Co-development Partner · 25 September 2024UB CAT (Center for Advanced Technology) awarded Vicora an R&D collaboration award in September 2024. The partnership provides funding and research support for life sciences development. Vicora also received UB CAT funding in December 2023.
  • Jacobs InstitutecoreStrategic or Co-development PartnerStrategic partner listed on Vicora's website alongside other industry partners. The Jacobs Institute is focused on vascular innovation and medical device development, aligned with Vicora's thrombectomy technology focus.
  • Yageo Group KEMETcoreStrategic or Co-development PartnerStrategic partner providing electronic components expertise. KEMET is a leading global manufacturer of electronic components that may support Vicora's catheter technology development.
  • Resolution MedicalcoreStrategic or Co-development PartnerStrategic partner listed on Vicora's website, specializing in medical device development with focus on interventional products.
  • Rookery LabsminorStrategic or Co-development PartnerListed as a strategic partner on Vicora's website, providing potential commercialization or business development support.
  • HemologyxminorStrategic or Co-development PartnerStrategic partner focused on hematology expertise relevant to Vicora's clot removal technology for DVT and PE treatment.
  • KCRI (Klein Cutler Research Institute)minorStrategic or Co-development PartnerListed as a strategic partner on Vicora's website, providing research institute collaboration for medical device development.
  • Eric RudieminorStrategic or Co-development PartnerListed as a strategic partner on Vicora's website, providing industry expertise in medical device development.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Vicora competitors and assessment

Company assessment

Direct peers

  • Penumbra: Penumbra's Indigo aspiration system is a leading mechanical thrombectomy platform for PE and DVT, directly competing with Vicora's Vibrato in the same hospital interventional radiology and cardiology call points.
  • Inari Medical (Stryker): Inari's FlowTriever (PE) and ClotTriever (DVT) are purpose-built mechanical thrombectomy devices and the closest direct competitors to Vicora Vibrato in the venous thromboembolism space.
  • AngioDynamics: AngioDynamics offers the AlphaVac and AngioVac mechanical thrombectomy systems, addressing PE and venous clot removal in the same hospital departments Vicora targets.
  • Argon Medical Devices: Argon manufactures the Option Elite and other venous intervention devices used for thrombectomy, positioning it as a competing supplier in DVT/PE clot-removal procedures.

Broad incumbents

  • Stryker: Through its 2025 acquisition of Inari Medical, Stryker is now a major player in venous mechanical thrombectomy; it also operates broader neurovascular and vascular franchises that overlap with Vicora's procedural category.
  • Boston Scientific: Boston Scientific has peripheral vascular and interventional cardiology franchises that compete in hospital procedural suites where thrombectomy is performed, even though it does not lead in mechanical PE/DVT.
  • Teleflex: Teleflex markets Arrow vascular access and interventional catheters used in the same hospital IR/cardiology settings, representing an incumbent catheter vendor at accounts Vicora would target.
  • Medtronic: Medtronic has peripheral and coronary interventional portfolios that overlap with the procedural call points and purchasing relationships Vicora will rely on at hospital systems.
  • Johnson & Johnson (Cerenovus): Cerenovus, J&J's neurovascular business, is a leading player in catheter-based clot retrieval (notably for stroke), bringing catheter thrombectomy R&D and sales capability adjacent to Vicora's venous use cases.

Emerging players

  • Imperative Care: Imperative Care is developing next-generation catheter-based vascular intervention technologies, with overlapping R&D culture and similar hospital call points in interventional radiology and cardiology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Vicora social profiles

Digital presence

Vicora financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vicora leadership team

Management profile

Number of profiles

Profiles10 records

Vicora funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vicora M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vicora

What does Vicora do?

Vicora is developing the Vicora Vibrato Thrombectomy System, described as the world's first catheter with an integrated distal tip vibration mechanism designed for mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures. The device is intended for use by interventional radiologists and interventional cardiologists in hospital settings, and requires no additional capital equipment for operation. The product is currently in pre-clinical testing (GLP study completed January 2026) and is not yet FDA cleared or commercially available.

Is Vicora a public or private company?

Vicora is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vicora founded?

Vicora was founded in 2020. It employs 1 to 10 people.

Where is Vicora based?

Vicora is headquartered in Buffalo, United States, in the North America region.

How does Vicora make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are securities Offering.

Who are Vicora's main competitors?

Direct peers on record are Penumbra, Inari Medical (Stryker), AngioDynamics and Argon Medical Devices. Broad incumbents are Stryker, Boston Scientific, Teleflex, Medtronic and Johnson & Johnson (Cerenovus). Imperative Care is listed as an emerging player.

Does Vicora have an API?

No public API is recorded for Vicora.

What industry is Vicora in?

Vicora's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals